• Atomo Diagnostics requests trading halt to update market on FDA response to FebriDx CLIA waiver application
• FebriDx test sales materially impact Atomo's Pascal cassette sales
• Trading halt to remain in place until earlier of market announcement or Monday, 30 March 2026

Atomo Diagnostics Limited (ASX: AT1) has requested an immediate trading halt for its securities (ASX: AT1) on the Australian Securities Exchange (ASX). The trading halt has been requested to enable the company to update the market on the FDA response to the FebriDx CLIA waiver application submitted by Lumos Diagnostics Holdings Ltd (ASX: LDX). Atomo is the exclusive licensor, manufacturer and supplier of Pascal cassettes to LDX for the FebriDx test, and the FDA decision on the CLIA waiver application will materially impact the volume of sales of the FebriDx test, each of which requires Atomo's Pascal cassette. The trading halt will remain in place until the earlier of the commencement of normal trading on Monday, 30 March 2026, or when Atomo's announcement regarding the FDA decision is released to the market. Atomo expects to make the announcement to the market before the start of normal trading on 30 March 2026.